Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE |
| April 19, 2021 | April 2021 Bond Updates |
|
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a... |
| View more at: https://www.prnewswire.com:443/news-releases/kazia-licenses-global-rights-to-evt801-a-novel-first-in-class-clinic-ready-vegfr3-inhibitor-from-evotec-se-301271363.html |
| Related News |